There is significant market demand for global sterile capacity says Recipharm. But as the need for COVID-19 vaccine filling decreases, competition between CDMOs will rise. Swedish contract development manufacturing organization (CDMO) Recipharm has made various investments across the globe to strengthen its fill-finish capabilities and capacity. In October, the firm scaled up its sterile filling capabilities by investing in Lab+ technology used for low volume blow-fill-seal (BFS) filling at its plant in Kaysersberg, France. Furthermore, the CDMO signed a Memorandum…